Who
Brian Savage
Interim Chief Legal Officer
Company insider
Files Form 4 as: Interim Chief Legal Officer, Teva Pharmaceutical Industries.
In numbers
- Trades disclosed
- 36
- Buys
- 0
- Sells
- 4
- Bought
- $0
- Sold
- $898K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 3 Mar 2026
- Last trade
- 18 Sep 2026
- Last filed
- 22 Sep 2026
Companies traded
Activity over time
1 Mar – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Sep 2026filed 22 Sep 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Code M | $156K4,503 at $34.70 | filing |
| 18 Sep 2026filed 22 Sep 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Sold | $174K4,503 at $38.69 | filing |
| 18 Sep 2026filed 22 Sep 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Sold | $99K2,525 at $39.15 | filing |
| 18 Sep 2026filed 22 Sep 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | $156K4,503 at $34.70 | filing |
| 18 Sep 2026filed 22 Sep 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Sold | $12K314 at $38.70 | filing |
| 18 Sep 2026filed 22 Sep 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | $156K4,503 at $34.70 | filing |
| 18 Sep 2026filed 22 Sep 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Code M | $156K4,503 at $34.70 | filing |
| 18 Sep 2026filed 22 Sep 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Sold | $174K4,503 at $38.69 | filing |
| 18 Sep 2026filed 22 Sep 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Sold | $99K2,525 at $39.15 | filing |
| 18 Sep 2026filed 22 Sep 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Sold | $12K314 at $38.70 | filing |
| 5 Mar 2026filed 9 Mar 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Code M | —3,580 | filing |
| 5 Mar 2026filed 9 Mar 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Sold | $36K1,127 at $31.67 | filing |
| 5 Mar 2026filed 9 Mar 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —3,580 at $0.00 | filing |
| 5 Mar 2026filed 9 Mar 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —3,580 at $0.00 | filing |
| 5 Mar 2026filed 9 Mar 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Code M | —3,580 | filing |
| 5 Mar 2026filed 9 Mar 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Sold | $36K1,127 at $31.67 | filing |
| 4 Mar 2026filed 6 Mar 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Code M | —4,744 | filing |
| 4 Mar 2026filed 6 Mar 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Sold | $48K1,489 at $32.46 | filing |
| 4 Mar 2026filed 6 Mar 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Code M | —3,466 | filing |
| 4 Mar 2026filed 6 Mar 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —4,744 at $0.00 | filing |
News
Brian Savage Sells 7,342 Shares of Teva Pharmaceutical Industries (NYSE:TEVA) Stockdailypolitical.com · 23 Sep 2026Comparing Harrow (NASDAQ:HROW) & Teva Pharmaceutical Industries (NYSE:TEVA)TEVA · tickerreport.com · 16 Oct 2026Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Raised to $50.00TEVA · dailypolitical.com · 15 Oct 2026Analyzing Astrazeneca (NYSE:AZN) & Teva Pharmaceutical Industries (NYSE:TEVA)TEVA · tickerreport.com · 13 Oct 2026
1 headline in the last 90 days name Brian Savage; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.